ProfileGDS5678 / 1449708_s_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 55% 55% 56% 56% 56% 53% 53% 53% 55% 55% 55% 56% 55% 55% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 13.4050155
GSM967853U87-EV human glioblastoma xenograft - Control 23.377955
GSM967854U87-EV human glioblastoma xenograft - Control 33.4225856
GSM967855U87-EV human glioblastoma xenograft - Control 43.3499756
GSM967856U87-EV human glioblastoma xenograft - Control 53.3524456
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 13.38253
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 23.372253
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 33.3103953
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 43.3585555
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 13.3704255
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 23.3602355
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 33.3619656
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 43.3741155
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 53.3698955